Biocon Enters Netherlands with Diabetes, Obesity Drugs; Expands GLP-1 Footprint in Europe

Biocon Limited has launched its GLP-1 based drug liraglutide in the Netherlands for the treatment of diabetes and obesity. This move is part of the company’s plan to grow its presence in the fast-expanding global metabolic care market.

Brands and Distribution

The drug-device combination will be distributed through partner Pharmamedic B.V. In the Netherlands, it will be sold as Diavorin for diabetes (generic of Victoza) and Vobexoryn for chronic weight management (generic of Saxenda).

Regulatory Approval and EU Milestone

The launch follows approval from the Netherlands’ Medicines Evaluation Board (MEB). This is the first European Union market where Biocon is introducing liraglutide under its own brand, marking an important milestone for the company.

Builds on UK and Global Expansion

This launch builds on Biocon’s entry into the UK in February, where it received approval from the MHRA. Earlier in India, the company also secured regulatory clearance for liraglutide to treat type 2 diabetes in adults and children above 10 years.

Partnerships to Speed Up Market Access

Biocon is using partnerships to expand faster. In 2024, it signed a licensing and supply deal with Tabuk Pharmaceuticals to sell GLP-1 products in select Middle East markets, with scope for future expansion.

Competing in a Growing Market

Demand for GLP-1 drugs is rising globally due to increasing obesity and diabetes cases. With this launch, Biocon aims to compete with leading global players such as Novo Nordisk and Eli Lilly.

Biocon Share Price Movement

Biocon share price (NSE: BIOCON) was trading at ₹390.20 on December 15, up 1% for the day. The stock opened at ₹389, touched an intraday high of ₹391.60 and a low of ₹383.55, giving the company a market capitalisation of about ₹46,800 crore. Biocon currently trades at a P/E ratio of 97.79, with a 52-week high of ₹424.95 and a 52-week low of ₹291. The company offers a modest dividend yield of 0.13%, with a quarterly dividend of ₹0.13 per share.

Conclusion

Biocon’s Netherlands launch strengthens its position in Europe and highlights its ambition to become a global player in diabetes and obesity treatment. Continued approvals and partnerships could support long-term growth in this high-demand segment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.